Loading clinical trials...
Loading clinical trials...
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
Conditions
Interventions
Mosunetuzumab (IV)
Mosunetuzumab (SC)
+3 more
Locations
29
United States
University of Alabama at Birmingham School of Medicine
Birmingham, Alabama, United States
City of Hope
Duarte, California, United States
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado, United States
University of Miami Miller School of Medicine
Miami, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
University of Michigan Hospital
Ann Arbor, Michigan, United States
Start Date
September 25, 2018
Primary Completion Date
January 30, 2024
Completion Date
July 20, 2025
Last Updated
November 29, 2024
NCT07523555
NCT05272384
NCT06189391
NCT05755087
NCT07123454
NCT06230224
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions